linjc16/ctgov huggingface dataset:
Relationship of Preoperative Parathyroid Hormone (PTH) and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy

Study Overview
=================
Brief Summary
-----------------
The intent for this study is to do a retrospective chart review of all patients who have undergone minimally invasive parathyroidectomy for primary hyperthyroidism. All data collected will be recorded under assigned identification numbers that will have no association with medical record or hospital numbers. Identifying characteristics will include age and sex. Anonymity will be upheld. The patient/family will not be contacted directly. All information will be obtained from the medical chart. Demographics, location, preoperative PTH levels and intraoperative Ex-Vivo gamma counts, co-morbid conditions, and the outcome based on the hospital notes will be obtained from patients' charts and will be transferred to a secure database. It is our hypothesis that there is a linear relationship between immediate preoperative parathyroid hormone (PTH) levels and Ex-Vivo gamma counts and the aim of this study is to better describe this relationship.

Official Title
-----------------
Relationship of Preoperative PTH and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy

Conditions
-----------------
Parathyroid Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be between the ages of 18 and 90 years old who have documented primary hyperparathyroidism and have undergone minimally invasive parathyroidectomy. Exclusion Criteria: Patients who have not had both intraoperative parathyroid hormone (PTH) levels and Gamma counts during their parathyroidectomy Patients who have parathyroidectomies for reasons other than primary hyperparathyroidism.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective Chart Review | The information presented in this report will provide a surgical tool for otolaryngologists to improve the efficiency and efficacy in patients with hyperparathyroid disease. | Retrospective Chart Review |
Immediate Nausea and Vomiting After the Administration of Non-ionic Contrast Media

Study Overview
=================
Brief Summary
-----------------
The prevalence of nausea and vomiting after the administration of non-ionic contrast media has rarely been assessed. Thus, the aim of our study is to evaluate the prevalence and risk factors of nausea and vomiting after the exposure to the non-ionic contrast media for computed tomography examinations in adults.

Detailed Description
-----------------
There is no robust evidence or guideline for fasting prior to contrast-enhanced CT scan in patients. Substantial heterogeneity exists on fasting prior to contrast-enhanced CT worldwide. Through dedicated questionnaires, the investigators plan to prospectively assess the prevalence and the risk factors for nausea and vomiting after the exposure to the non-ionic contrast media agent in adult patients undergoing computed tomography examinations.

Official Title
-----------------
Immediate Nausea and Vomiting After the Administration of Non-ionic Contrast Media: Prevalence and Risk Factors

Conditions
-----------------
Contrast Agent, Nausea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patients undergoing contrast-enhanced CT examination with non-ionic contrast media during regular working hours Adult patients (20 years old or older) Patients with informed written consent Patients under observation by medical staffs during and after CT examination up to 30 minutes. Exclusion criteria: Patients without informed written consent Age of patients younger than 20 years old Uncooperative patients Pediatric, pregnant, and emergent patients Patients without sufficient observation by medical staffs during and after CT examination up to 30 minutes.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with enhanced CT scan<br>Patients undergo CT examination after the administration of non-ionic contrast media for clinical need. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of immediate nausea or vomiting after contrast injection | Patients will be observed for 30 minutes after the administration of the contrast media agent and medical staffs will record and evaluate the patients' status and the severity of gastrointestinal reaction to the contrast media agent such as nausea or vomiting. | For 30 minutes after administration of non-ionic contrast media | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nausea, Vomiting, Non-ionic contrast media, Side effect
Ga-68-NODAGA-MJ9 Compared to F-18-FCH PET/CT for Prostate Cancer Patients

Study Overview
=================
Brief Summary
-----------------
Prostate cancer patients for whom a F-18-FCH PET/CT is indicated. Ga-68-NODAGA-MJ9 is a new PET/CT radiotracer aiming at giving complementary information : more precise images and early localisation of recurrence to standard imaging

Detailed Description
-----------------
Patient with primary or relapsing prostate cancer for whom F-18-FCH PET/CT is indicated will be proposed to participate to the present study. After signing the patient informed consent, both F-18-FCH and Ga-68-NODAGA-MJ9 PET/CT will be scheduled with a maximum 10 day-interval. No adverse events are expected.

Official Title
-----------------
PET/CT Study of GRP Receptors With Ga-68-NODAGA-MJ9 in Prostate Cancer Compared to F-18-FCH PET / CT

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: 1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age : adult patients Karnofsky : ≥ 80% Patients with histologically proven prostate cancer for whom 18F-fluocholine PET/CT is indicated for primary cancer staging, or for recurrence with increase of blood PSA. In order to provide a detection probability of 30% or more, a blood PSA 0.5 ng / ml or more in post initial curative intent surgery will be required. Signed informed consent. Exclusion Criteria: Lack of discernment to sign the consent form Age <18 years Patient under hormonal treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| F-18-FCH & Ga-68-NODAGA-MJ9<br>1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9 | Diagnostic Test: 1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9<br>* Each patient will have two PET/CT<br>* Other names: 1 PET/CT with Ga-68-NODAGA-MJ9;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positivity of the new radiotracer Ga-68-NODAGA-MJ9 compared to the standard radiotracer F-18-FCH | PET images : SUVmax, SUVmean, VOI (mL), SUV41% lesions/ SUVbackground CT images : size lesions measured in 3D (axial, coronal and sagittal), density in Hounsfield Units (HU) | At baseline (after F-18-FCH PET/CT) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
recurrence, prostate cancer, primary, F-18-FCH PET/CT, Ga-68-NODAGA-MJ9 PET/CT
Pilot Study of the Ablative Fractional CO2 Laser in Hypertrophic Scars in Adult Burn Patients

Study Overview
=================
Brief Summary
-----------------
This is a randomized, controlled, within-patient, single-blinded, pilot study that will evaluate the impact of laser treatment on burn HSc relative to self-matched control scars. The studied primary outcomes of treatment are scar pliability, thickness, vascularity, pain, itch and patient satisfaction.

Detailed Description
-----------------
Prior to treatment initiation, two independent scars sites will be selected and an anatomically- on each individual. At the selected treatment site the scar will be treated with the CORE fractional CO2 laser Participants will receive 3 treatment sessions scheduled 4 weeks apart. The scar sites will be evaluated at baseline, immediately before the 3rd treatment and 12 weeks after their final treatment session.

Official Title
-----------------
Randomized, Controlled, Within-patient, Single-blinded Pilot Study to Evaluate the Efficacy of the Ablative Fractional CO2 Laser in the Treatment of Hypertrophic Scars in Adult Burn Patients

Conditions
-----------------
Burns

Intervention / Treatment
-----------------
* Procedure: Laser treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fitzpatrick skin type <IV (37), Have sustained a thermal burn injury, Have at least 2 independent sites that show clinical evidence of HSc, Are 2 months or more post-injury. Exclusion Criteria: Subjects with skin phototypes IV or higher, With history of keloidal scarring, Who have coagulation disorder, Are taking immunosuppressive medications, If the mechanism of injury is an electrical, chemical, or cold injury, Any underlying active skin disease, Have taken oral Isotreinoin within the last 6 months, Photosensitivity or have taken photosensitizing medications, Pregnancy, Previous treatment with dermabrasion, chemical peel, laser or intense pulsed light treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Laser treated HSc scar<br>Co2 laser treatment | Procedure: Laser treatment<br>* CORE fractional CO2 laser treatment<br>|
| No Intervention: Control scar<br>Standard care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Skin Characteristics changes | Erythema, elasticity and thickness measures | baseline, 12 weeks and 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Satisfaction Questionnaire | Questionnaire | baseline, 24 weeks |
Effects of Phenolic Acids on Endothelial Function

Study Overview
=================
Brief Summary
-----------------
Epidemiological studies suggest dietary (poly) phenols decrease the risk of death from cardiovascular diseases. (Poly)phenol-rich foods include fruits and vegetables as well as tea, coffee, red wine, and chocolate. The aim of the present study is to investigate whether endothelial function is altered by ingestion of phenolic acids. Moreover, the investigators will evaluate the effect of phenolic acids on blood pressure and platelet adhesion.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Phenolic acids


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy males Smokers Exclusion Criteria: Any food allergy Abnormal blood pressure defined as follow: systolic <100 or >160 mmHg and diastolic <50 or >100mmHg Regular consumption of medication within 2 months before the study inclusion Caffeine intake 1 day before screening measurements (and 1 day before each visit), Any intake of multivitamin-tablets and other supplemental compounds 10 days before the study start and throughout the study. Excessive alcohol intake defined as > 280 g per week

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: phenolic acids<br>Maltodextrine + Phenolic acids | Other: Phenolic acids<br>* Phenolic acids<br>|
| Placebo Comparator: placebo<br>Maltodextrine | Other: Phenolic acids<br>* Phenolic acids<br>|
| Experimental: phenolic acid<br>Maltodextrine + Phenolic acids | Other: Phenolic acids<br>* Phenolic acids<br>|
| Active Comparator: polyphenol<br> | Other: Phenolic acids<br>* Phenolic acids<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endothelial dysfunction |  | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
subjects
Effect of Gastric Bypass Surgery on Pancreatic Islet and Incretin Function - Follow-up Study

Study Overview
=================
Brief Summary
-----------------
To examine pancreatic islet function and incretin function during intravenous and oral stimulation >2 years after gastric bypass surgery in patients with normal glucose tolerance. We hypothesize that islet cell and incretin function is enhanced in response to oral, but not intravenous, stimulation - i.e. incretin released from the gut in response to oral stimulation play a key role for the enhanced islet function after gastric bypass surgery.

Conditions
-----------------
Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participation in previous study (NCT01559779) Exclusion Criteria: Pregnancy/lactation Major chronic disease develop since previous examination with possible impact on outcomes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br>Morbidly obese patients with normal glucose tolerance undergoing gastric bypass surgery | |
| Controls<br>Age, sex and BMI-matched healthy controls | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in islet cell function from baseline (preoperatively) | Change in insulin and glucagon secretion during oral and intravenous stimulation after gastric bypass | >24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in glucose tolerance during oral glucose tolerance test | Fasting, peak and nadir glucose during oral glucose tolerance test | >24 months | 
| Arterio-venous glucose difference during oral glucose tolerance test after gastric bypass | Differences in arterial and venous plasma glucose during oral glucose stimulation | >24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity, Gastric Bypass, Bariatric Surgery, Incretin Function, Islet Function
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.

Official Title
-----------------
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation

Conditions
-----------------
Engraftment Syndrome

Intervention / Treatment
-----------------
* Drug: Budesonide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Patients 18-80 years of age with a diagnosis of a hematological malignancy Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies Exclusion Criteria: • Patients enrolled in investigational clinical trials Sct for non hematologic malignancies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Budesonide<br> | Drug: Budesonide<br>* budesonide starting day 5 after transplant<br>|
| No Intervention: nothing<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| non-infectious fever | non infectious fever defined as fever without identified infection that occurs up to 3 days prior and 10 days after the day of engraftment in patients on budesonide prophylaxis compared to patients who will not receive prophylaxis | 30 days post stem cell transplant |
Turkish Version of the Kinesthetic and Visual Imagery Questionnaire

Study Overview
=================
Brief Summary
-----------------
Imagery is determined with two strategies to mentally simulate the movements: visual and kinesthetic imagery. Visual motor imagery (VMI) is associated with spatial coordinates of a movement in the environment and through this speciality VMI applies mainly to the imagery of moving objects or to movement of another person in the imagined environment, although imagine of own movement is also possible. Kinesthetic motor imagery depends on dynamic relationship among the individual, the movement and the environment and it should be determined by the nature of the task, the environment and individual characteristics and also requires feel the movement. The aim of this study is to translate this questionnaire into Turkish and the translation in terms of its internal consistency, test-retest reliability.

Official Title
-----------------
Reliability and Validity of the Turkish Version of the Kinesthetic and Visual Imagery Questionnaire

Conditions
-----------------
Image, Body, Healthy, Pain

Intervention / Treatment
-----------------
* Behavioral: Determine what the imagery levels are


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ages between 18-65 years, healthy volunteers, with no limitation in mobility or movement disorder, with no chronic pain Exclusion Criteria: refuse to attend to the study, neurological conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cronbach's Alpha coefficient | Cronbach's Alpha coefficient was used to determine internal consistency of the questionnaire and its subscales. Cronbach's Alpha Coefficient greater than 0.8 is generally considered acceptable. | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
reliability, motor imagery, kinesthetic imagery, Turkish version
Can a Rapid 2 Day Followup After Discharge From the ED Reduce Readmissions and Death for Patients 75 Years and Older?

Study Overview
=================
Brief Summary
-----------------
Our hypothesis is that a rapid follow up for elderly patients in a Geriatric Clinic discharged from the Emergency Department (ED) will have fewer unplanned return ED visits and fewer unplanned hospital admissions with no attendant increase in mortality. Patients 75 years of age and older will be randomized following discharge from the ED into two groups. The first will receive standard post ED care. The second will receive an appointment to our Geriatric Clinic within 2-3 days for stabilization, further treatment and contact with the patient's primary physician to communicate the course of the patient's illness and to schedule subsequent follow-up with the patients regular medical provider. There will be two primary outcomes: The first will be a composite of morality and/or return to the ED at 30 days, and the secondary primary outcome will be mortality. Economic data regarding resource utilization by patients will also be analyzed.

Official Title
-----------------
A Randomized Trial of the Effect of a Geriatrics Appointment Within 2-3 Days of Discharge From the Emergency Department(ED) in Reducing ED and Hospital Readmissions for Patients 75 Years of Age and Older.

Conditions
-----------------
Emergencies

Intervention / Treatment
-----------------
* Other: 2-3 day return appointment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients 75 years of age and older discharged from the ED Exclusion Criteria: Younger than 75.

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>Standard post ED care | |
| Experimental: 2-3 day return appointment<br>Patients will receive further treatment in Geriatric Clinic 2-3 days post ED discharge. | Other: 2-3 day return appointment<br>* 2-3 appointment in geriatric clinic following ED discharge<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality and readmissions to emergency department |  | 30 and 180 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Secondary outcome to measure all cause mortality for patients admitted to the study. | 30 and 180 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Emergency department, Geriatrics, mortality, readmission rates., Patients 75 years of age and older.